Genscript Biotech (1548) Stock Forecast & Price Target

Compare

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1548 Analyst Ratings

Moderate Buy

1 Buy

0 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Genscript

Biotech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1548 Stock 12 Month Forecast

Average Price Target

HK$21.88

▲(97.84% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Genscript Biotech in the last 3 months. The average price target is HK$21.88 with a high forecast of HK$21.88 and a low forecast of HK$21.88. The average price target represents a 97.84% change from the last price of HK$11.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"HK$10","23":"HK$23","13.25":"HK$13.25","16.5":"HK$16.5","19.75":"HK$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21.880819356,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$21.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.880819356,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$21.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.880819356,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$21.88</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,13.25,16.5,19.75,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2021","6":"Dec<br/>2021","9":"Sep<br/>2023","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.72,13.424678412,14.129356824,14.834035236,15.538713648,16.24339206,16.948070472,17.652748884,18.357427296,19.062105708,19.76678412,20.471462532,21.176140944,{"y":21.880819356,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.72,13.424678412,14.129356824,14.834035236,15.538713648,16.24339206,16.948070472,17.652748884,18.357427296,19.062105708,19.76678412,20.471462532,21.176140944,{"y":21.880819356,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.72,13.424678412,14.129356824,14.834035236,15.538713648,16.24339206,16.948070472,17.652748884,18.357427296,19.062105708,19.76678412,20.471462532,21.176140944,{"y":21.880819356,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.7,"date":1622505600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.7,"date":1625097600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.7,"date":1627776000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.7,"date":1630454400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.7,"date":1633046400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.7,"date":1635724800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.7,"date":1638316800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.7,"date":1640995200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.7,"date":1640995200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":22.7,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.64,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$21.88

Average Price TargetHK$21.88

Lowest Price TargetHK$21.88

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Morgan Stanley

Reiterated

03/14/25

xxxxxxxxxxxxx

Chris Lui

Jefferies

HK$23

Buy

107.96%

Upside

Reiterated

06/02/24

Buy Rating on Genscript Biotech Amidst Market Volatility and Geopolitical Tensions: An Undervalued Opportunity

Yang Huang

J.P. Morgan

HK$27→HK$16

Buy

44.67%

Upside

Reiterated

05/17/24

Genscript Biotech Corp (1548:HK) PT Lowered to HK$16 at JPMorganJPMorgan analyst Yang Huang lowered the price target on Genscript Biotech Corp (1548:HK) to HK$16.00 (from HK$27.00) while maintaining a Overweight rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Morgan Stanley

Reiterated

03/14/25

xxxxxxxxxxxxx

Chris Lui

Jefferies

HK$23

Buy

107.96%

Upside

Reiterated

06/02/24

Buy Rating on Genscript Biotech Amidst Market Volatility and Geopolitical Tensions: An Undervalued Opportunity

Yang Huang

J.P. Morgan

HK$27→HK$16

Buy

44.67%

Upside

Reiterated

05/17/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Genscript Biotech

Which Analyst Should I Follow If I Want to Buy HK:1548 and Sell After:

1 Month

xxx

Success Rate

0/1 ratings generated profit

Average Return

-13.50%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 0.00% of your transactions generating a profit, with an average return of -13.50% per trade.

3 Months

xxx

Success Rate

1/1 ratings generated profit

Average Return

+20.90%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +20.90% per trade.

1 Year

Chris LuiJefferies

Success Rate

1/1 ratings generated profit

Average Return

+0.70%

reiterated a buy rating 11 months ago

Copying Chris Lui's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +0.70% per trade.

2 Years

xxx

Success Rate

1/1 ratings generated profit

Average Return

+0.70%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +0.70% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1548 Analyst Recommendation Trends

Rating

Jan 22

Sep 23

Mar 24

May 24

Mar 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1548 has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1548 average Analyst price target in the past 3 months is 21.88.

Each month's total comprises the sum of three months' worth of ratings.

1548 Financial Forecast

1548 Earnings Forecast

Next quarter’s earnings estimate for 1548 is HK$0.62 with a range of HK$0.62 to HK$0.62. The previous quarter’s EPS was HK$11.49. 1548 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.40% of the time in the same period. In the last calendar year 1548 has Outperformed its overall industry.

1548 Sales Forecast

Next quarter’s sales forecast for 1548 is HK$4.35B with a range of HK$4.35B to HK$4.35B. The previous quarter’s sales results were ―. 1548 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.92% of the time in the same period. In the last calendar year 1548 has Outperformed its overall industry.

1548 Stock Forecast FAQ

What is HK:1548’s average 12-month price target, according to analysts?

Based on analyst ratings, Genscript Biotech Corporation’s 12-month average price target is 21.88.

What is HK:1548’s upside potential, based on the analysts’ average price target?

Genscript Biotech Corporation has 97.84% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Genscript Biotech Corporation a Buy, Sell or Hold?

Genscript Biotech Corporation has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.

What is Genscript Biotech Corporation’s share price target?

The average share price target for Genscript Biotech Corporation is 21.88. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$21.88 ,and the lowest forecast is HK$21.88. The average share price target represents 97.84% Increase from the current price of HK$11.06.

What do analysts say about Genscript Biotech Corporation?

Genscript Biotech Corporation’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Genscript Biotech Corporation?

To buy shares of HK:1548, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Genscript Biotech (1548) Stock Forecast & Price Target

1548 Analyst Ratings

1548 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Genscript Biotech

1548 Analyst Recommendation Trends

1548 Financial Forecast

1548 Earnings Forecast

1548 Sales Forecast

1548 Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts